Screen the A10 antibody for off-target binding to plasma membrane proteins and secreted proteins
Award Notice Posted
- Solicitation number
- 75N91026P00004
- Agency
-
Office of the Assistant Secretary for Administration
Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N91026P00004 Federal contract award
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- 6640 Laboratory Equipment And Supplies
- Place of performance
- Saffron Essex United Kingdom
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Cancer Institute (NCI), operating under the Department of Health and Human Services Office of the Assistant Secretary for Administration, awarded a firm fixed-price contract valued at $38,750.00 to Charles River Discovery Research Services UK Limited on January 27, 2026 (Contract No. 75N91026P00004). Under this contract, the contractor will conduct an off-target binding screen of the A10 antibody to identify any unintended interactions with plasma membrane proteins and secreted proteins that could potentially cause adverse side effects in cancer patients. The A10 antibody is currently being developed by NCI as a therapeutic agent to target cancer cells expressing high levels of epidermal growth factor receptor, and while extensively tested, the off-target binding assessment is necessary to ensure patient safety before clinical application.
Notice text
This is a Firm Fixed Priced purchase order. NCI solicited and negotiated directly with Charles River Discovery Research Services UK Limited. The National Cancer Institute (NCI) has a program to use an antibody called, 'A10' to target cancer cells that have a lot of the epidermal growth factor receptor on their cell surface. While this antibody has been extensively tested and characterized it is not known if it also binds any other cell surface proteins. The contractor shall perform an off-target screen on an NCI antibody and report back on any problematic interactions that could predict a serious side effect should the antibody be given to a cancer patient. The A10 is NOT known to bind other cell surface proteins or secreted proteins but this needs to be addressed in the off-target screen.
Awarded contract 75N91026P00004 to CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED for 38750.00 on 2026-01-27.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity